KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) EBIT (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of EBIT data on record, last reported at -$28.8 million in Q4 2025.

  • For Q4 2025, EBIT fell 112.38% year-over-year to -$28.8 million; the TTM value through Dec 2025 reached -$71.1 million, down 130.9%, while the annual FY2025 figure was -$71.1 million, 130.9% down from the prior year.
  • EBIT reached -$28.8 million in Q4 2025 per AQST's latest filing, down from -$11.5 million in the prior quarter.
  • Across five years, EBIT topped out at $55000.0 in Q2 2024 and bottomed at -$28.8 million in Q4 2025.
  • Average EBIT over 5 years is -$9.7 million, with a median of -$8.9 million recorded in 2022.
  • Peak YoY movement for EBIT: soared 101.31% in 2024, then crashed 20769.09% in 2025.
  • A 5-year view of EBIT shows it stood at -$11.7 million in 2021, then rose by 8.19% to -$10.7 million in 2022, then soared by 63.49% to -$3.9 million in 2023, then plummeted by 247.2% to -$13.6 million in 2024, then tumbled by 112.38% to -$28.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$28.8 million in Q4 2025, -$11.5 million in Q3 2025, and -$11.4 million in Q2 2025.